Results 311 to 320 of about 337,810 (339)
Some of the next articles are maybe not open access.
Novel anticoagulants and the future of anticoagulation
Thrombosis Research, 2009Since its discovery during the first half of the 20th century by biochemists at the University of Wisconsin, warfarin (along with other vitamin K antagonists) has remained the only oral anticoagulant available to patients at risk for thromboembolism. After nearly 6 decades in clinical practice, we have learned much about warfarin. Although it is highly
openaire +3 more sources
2006
Because of the narrow therapeutic index of warfarin and unfractionated heparin (UFH), monitoring their anticoagulant effects is required. On the other hand, lowmolecular- weight heparin (LMWH) and fibrinolytic agents need to be monitored only under certain circumstances.
Richard C. Becker, Frederick A. Spencer
openaire +1 more source
Because of the narrow therapeutic index of warfarin and unfractionated heparin (UFH), monitoring their anticoagulant effects is required. On the other hand, lowmolecular- weight heparin (LMWH) and fibrinolytic agents need to be monitored only under certain circumstances.
Richard C. Becker, Frederick A. Spencer
openaire +1 more source
Anticoagulation clinics and the monitoring of anticoagulant therapy
International Journal of Cardiology, 1988Patients attending an anticoagulation clinic were studied to delineate predisposing risk factors for bleeding and thromboembolic episodes. Seventy-three patients were observed for a total of 921.8 patient-treatment months. The mean duration of treatment was 12.6 months (range 3-36 months).
Richard Charney +3 more
openaire +3 more sources
Arthritis & Rheumatism, 1976
AbstractThe clinical and laboratory experience with the lupus anticoagulant was reviewed in 37 patients. The anticoagulant is thought to act by blocking the activation of prothrombin by the prothrombin activator complex of factors Xa, V, and phospholipid.
Michael Boxer +2 more
openaire +3 more sources
AbstractThe clinical and laboratory experience with the lupus anticoagulant was reviewed in 37 patients. The anticoagulant is thought to act by blocking the activation of prothrombin by the prothrombin activator complex of factors Xa, V, and phospholipid.
Michael Boxer +2 more
openaire +3 more sources
Anticoagulation in the elderly
Current Opinion in Pulmonary Medicine, 2001Oral anticoagulation therapy has demonstrated benefit in the treatment and prevention of a variety of thromboembolic disorders. Most individuals who receive oral anticoagulant therapy are elderly patients with nonvalvular atrial fibrillation and acute or recurrent venous thromboembolism.
Richard H. White, Mark C Henderson
openaire +2 more sources
Cardiology Clinics, 2012
Pregnancy-associated thrombosis is an important cause of morbidity and mortality during pregnancy. Anticoagulation therapy is an important component of the management of thrombotic complications in pregnancy but may result in fetal and maternal complications.
Sorel Goland, Uri Elkayam
openaire +3 more sources
Pregnancy-associated thrombosis is an important cause of morbidity and mortality during pregnancy. Anticoagulation therapy is an important component of the management of thrombotic complications in pregnancy but may result in fetal and maternal complications.
Sorel Goland, Uri Elkayam
openaire +3 more sources
Anticoagulants and Anticoagulation
Medical Clinics of North America, 1976Christos B. Moschos, Murray Nussbaum
openaire +3 more sources
2010
Low molecular weight heparins (LMWH) have largely replaced unfractionated heparin. Their much more predictable anticoagulant response combined with high bioavailability after subcutaneous injection means that the dose can be calculated by body weight and given subcutaneously without any monitoring or dose adjustment.
openaire +1 more source
Low molecular weight heparins (LMWH) have largely replaced unfractionated heparin. Their much more predictable anticoagulant response combined with high bioavailability after subcutaneous injection means that the dose can be calculated by body weight and given subcutaneously without any monitoring or dose adjustment.
openaire +1 more source
Journal of Thrombosis and Thrombolysis, 2006
Venous thromboembolic (VTE) complications are a leading cause of maternal mortality in the developed world. To reduce the incidence of VTE in pregnancy, and improve outcomes, a wider understanding of the risk factors involved and a better identification of women at risk of thrombosis coupled with effective thromboprophylaxis and treatment of VTE are ...
openaire +3 more sources
Venous thromboembolic (VTE) complications are a leading cause of maternal mortality in the developed world. To reduce the incidence of VTE in pregnancy, and improve outcomes, a wider understanding of the risk factors involved and a better identification of women at risk of thrombosis coupled with effective thromboprophylaxis and treatment of VTE are ...
openaire +3 more sources